A estratégia Watch and Wait constitui uma alternativa ao tratamento cirúrgico do cancro do recto?
Downloads
Download data is not yet available.
References
Heald RJ, Beets G, Carvalho C. Response to chemoradiotherapy in rectal cancer – predictor of cure and a crucial new choice for the patient. Colorectal Dis 2014;16:327-330.
O que há de novo no tratamento do cancro do reto. Revista Portuguesa de Cirurgia 2014
TaylorFG, Quirke P, Heald RJ et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicentre, European study. Ann Surg 2011;253:711-719
Habr-Gama A, Perez RO, Wynn G et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: Characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010;53:1692-1698.
Lambregts DM, Maas M, Bakers FC et al. Long-term follow-up features on rectal MRI during a wait-and-see approach after a clinical complete response in patients with rectal cancer treated with chemoradiotherapy. Dis Colon Rectum 2011:54:1521-1528.
Smith FM, Chang KH, Sheaham N K et al. The surgical significance of residual mucosal abnormalitiesin rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg 2012;99:993-1001.
Smith FM, Wiland H, Maas A et al Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiothery. Dis Colon Rectum 2014;57:311-315.
Duldulao MP, Lee W, Streja L et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum 2013;56:142-149.
Leite J, Manso A, Oliveira A et al. Predicting lymph node metastases and recurrence in patients with ypT0-1 rectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis 2014;16 (Suppl3):30.
Park IJ, You YN, Skibber JM et al. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancer after neoadjuvant chemoradiotherapy. Dis Colon Rectum 2013;56:135-141.
Gantt GA, Che Y, Dejulius K et al. Gene expression profile is associated with chemoradiation resistence in rectal cancer. Colorectal Dis 2014;16:57-66.
Garcia-Aguilar J1, Shi Q, Thomas CR Jr, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol. 2012;19:384-91.
Garcia-Aguilar J1, Thomas CR Jr, Renfro LA et al. Recurrence and survival in patients with UT2UN0 rectal cancer (RC) treated with neoadjuvant chemoradiation (CRT) and local excision (LE): results of the ACOSOG Z6041 trial. Colorectal Dis 2014 (Suppl.3):2.
Foster JD1, Jones EL, Falk S, et al. Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum. 2013; 56: 921-930.
O que há de novo no tratamento do cancro do reto. Revista Portuguesa de Cirurgia 2014
TaylorFG, Quirke P, Heald RJ et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicentre, European study. Ann Surg 2011;253:711-719
Habr-Gama A, Perez RO, Wynn G et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: Characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010;53:1692-1698.
Lambregts DM, Maas M, Bakers FC et al. Long-term follow-up features on rectal MRI during a wait-and-see approach after a clinical complete response in patients with rectal cancer treated with chemoradiotherapy. Dis Colon Rectum 2011:54:1521-1528.
Smith FM, Chang KH, Sheaham N K et al. The surgical significance of residual mucosal abnormalitiesin rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg 2012;99:993-1001.
Smith FM, Wiland H, Maas A et al Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiothery. Dis Colon Rectum 2014;57:311-315.
Duldulao MP, Lee W, Streja L et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum 2013;56:142-149.
Leite J, Manso A, Oliveira A et al. Predicting lymph node metastases and recurrence in patients with ypT0-1 rectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis 2014;16 (Suppl3):30.
Park IJ, You YN, Skibber JM et al. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancer after neoadjuvant chemoradiotherapy. Dis Colon Rectum 2013;56:135-141.
Gantt GA, Che Y, Dejulius K et al. Gene expression profile is associated with chemoradiation resistence in rectal cancer. Colorectal Dis 2014;16:57-66.
Garcia-Aguilar J1, Shi Q, Thomas CR Jr, et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol. 2012;19:384-91.
Garcia-Aguilar J1, Thomas CR Jr, Renfro LA et al. Recurrence and survival in patients with UT2UN0 rectal cancer (RC) treated with neoadjuvant chemoradiation (CRT) and local excision (LE): results of the ACOSOG Z6041 trial. Colorectal Dis 2014 (Suppl.3):2.
Foster JD1, Jones EL, Falk S, et al. Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum. 2013; 56: 921-930.
Published
2015-12-01
How to Cite
LEITE, Júlio Soares.
A estratégia Watch and Wait constitui uma alternativa ao tratamento cirúrgico do cancro do recto?.
Revista Portuguesa de Cirurgia, [S.l.], n. 35, p. 10-11, dec. 2015.
ISSN 2183-1165.
Available at: <https://revista.spcir.com/index.php/spcir/article/view/548>. Date accessed: 25 apr. 2024.
Section
Editorials
